BRPI1010517A2 - métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal - Google Patents
métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomalInfo
- Publication number
- BRPI1010517A2 BRPI1010517A2 BRPI1010517A BRPI1010517A BRPI1010517A2 BR PI1010517 A2 BRPI1010517 A2 BR PI1010517A2 BR PI1010517 A BRPI1010517 A BR PI1010517A BR PI1010517 A BRPI1010517 A BR PI1010517A BR PI1010517 A2 BRPI1010517 A2 BR PI1010517A2
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- methods
- lysosomal storage
- storage diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810909P | 2009-04-09 | 2009-04-09 | |
| PCT/US2010/030472 WO2010118283A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating lysosomal storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010517A2 true BRPI1010517A2 (pt) | 2017-01-31 |
Family
ID=42934559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010517A BRPI1010517A2 (pt) | 2009-04-09 | 2010-04-09 | métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8940766B2 (https=) |
| EP (1) | EP2416656B1 (https=) |
| JP (1) | JP5645918B2 (https=) |
| CN (1) | CN102625661B (https=) |
| AU (1) | AU2010233188B2 (https=) |
| BR (1) | BRPI1010517A2 (https=) |
| CA (1) | CA2758271C (https=) |
| ES (1) | ES2564093T3 (https=) |
| IL (1) | IL215583A (https=) |
| NZ (1) | NZ595629A (https=) |
| WO (1) | WO2010118283A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| BRPI1015472A2 (pt) * | 2009-04-09 | 2015-11-24 | Amicus Therapeutics Inc | métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central |
| KR101880411B1 (ko) | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| KR20230066482A (ko) * | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| US9598438B2 (en) * | 2014-02-12 | 2017-03-21 | Amicus Therapeutics, Inc. | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| KR20250007693A (ko) | 2015-12-30 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| AU2017239641A1 (en) | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| ATE156344T1 (de) | 1991-04-25 | 1997-08-15 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| EP0679088B1 (en) | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| ATE243196T1 (de) | 1994-03-09 | 2003-07-15 | Novo Nordisk As | Piperidine und pyrrolidine |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20060079533A1 (en) * | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| EP1558245A2 (en) | 2002-10-28 | 2005-08-03 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| CA2545433A1 (en) * | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| WO2007150064A2 (en) * | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| WO2010048532A1 (en) | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| BRPI1015472A2 (pt) * | 2009-04-09 | 2015-11-24 | Amicus Therapeutics Inc | métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central |
-
2010
- 2010-04-09 BR BRPI1010517A patent/BRPI1010517A2/pt not_active Application Discontinuation
- 2010-04-09 EP EP10762469.4A patent/EP2416656B1/en not_active Not-in-force
- 2010-04-09 ES ES10762469.4T patent/ES2564093T3/es active Active
- 2010-04-09 CN CN201080023544.XA patent/CN102625661B/zh not_active Expired - Fee Related
- 2010-04-09 US US12/757,160 patent/US8940766B2/en active Active
- 2010-04-09 CA CA2758271A patent/CA2758271C/en not_active Expired - Fee Related
- 2010-04-09 NZ NZ595629A patent/NZ595629A/xx not_active IP Right Cessation
- 2010-04-09 JP JP2012504881A patent/JP5645918B2/ja not_active Expired - Fee Related
- 2010-04-09 AU AU2010233188A patent/AU2010233188B2/en not_active Ceased
- 2010-04-09 WO PCT/US2010/030472 patent/WO2010118283A1/en not_active Ceased
-
2011
- 2011-10-06 IL IL215583A patent/IL215583A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010233188B2 (en) | 2015-07-16 |
| WO2010118283A1 (en) | 2010-10-14 |
| AU2010233188A1 (en) | 2011-11-03 |
| CA2758271C (en) | 2018-06-05 |
| JP2012523431A (ja) | 2012-10-04 |
| CN102625661B (zh) | 2015-05-27 |
| IL215583A (en) | 2016-09-29 |
| IL215583A0 (en) | 2011-12-29 |
| ES2564093T3 (es) | 2016-03-17 |
| US8940766B2 (en) | 2015-01-27 |
| CN102625661A (zh) | 2012-08-01 |
| EP2416656B1 (en) | 2015-12-23 |
| EP2416656A4 (en) | 2012-09-05 |
| NZ595629A (en) | 2013-04-26 |
| JP5645918B2 (ja) | 2014-12-24 |
| EP2416656A1 (en) | 2012-02-15 |
| US20100260740A1 (en) | 2010-10-14 |
| CA2758271A1 (en) | 2010-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010517A2 (pt) | métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal | |
| PT2470191E (pt) | Métodos e composições para prevenção ou tratamento de doenças oftálmicas | |
| HUE049880T2 (hu) | Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére | |
| IL226049A0 (en) | Composition for use in the prevention and/or treatment of skin conditions and skin diseases | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| BR112014002619A2 (pt) | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica | |
| ZA201202596B (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| BRPI1008909A2 (pt) | métodos e sistema de tratamento de veia | |
| BRPI0921321A2 (pt) | métodos para o tratamento de indwcções e tumores | |
| IL258794B (en) | Methods and compositions for diagnosis and treatment of cancer | |
| BR112013016535A2 (pt) | extratos vegetais para o tratamento e prevenção de infecções | |
| EP2155197A4 (en) | TREATMENT OF LYSOSOMAL STORAGE DISEASES | |
| IL207360A0 (en) | Methods of diagnosing and treating parp - mediated diseases | |
| GB2496794B (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| BRPI1008566A2 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| PT2796457T (pt) | Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação | |
| PT2582683T (pt) | Tratamento da gota e de hiperuricemia | |
| PL2435825T3 (pl) | Sposoby leczenia chorób | |
| HRP20181608T1 (hr) | Korištenje inhibitora pde7 u liječenju bolesti kretanja | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BRPI1015472A2 (pt) | métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central | |
| PT2613798E (pt) | Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes | |
| HRP20150052T1 (xx) | Fungicidni pripravak i postupak za suzbijanje bolesti biljaka | |
| BR112012002265A2 (pt) | composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios | |
| ZA201105284B (en) | Visfatin therapeutic agents for the treatment of acne and other conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |